Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD

seekingalpha08-16

Lykos Therapeutics, the privately held psychedelic drug developer, is letting go of 75% of its employees following the U.S. FDA's decision earlier in August to reject its application for an MDMA-based...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459401548?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/882024294/image_882024294.jpg","is_english":true,"pubTime":"2024-08-16 03:02","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2459401548","market":"sg","top_or_hot":-1,"title":"Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD","media":"seekingalpha","content":"<div>\n<p>Lykos Therapeutics, the privately held psychedelic drug developer, is letting go of 75% of its employees following the U.S. FDA's decision earlier in August to reject its application for an MDMA-based...</p>\n\n<a href=\"https://seekingalpha.com/news/4140729-lykos-laying-off-75-workforce-following-fda-rejection-psychedelic-drug-ptsd\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-16 03:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4140729-lykos-laying-off-75-workforce-following-fda-rejection-psychedelic-drug-ptsd><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lykos Therapeutics, the privately held psychedelic drug developer, is letting go of 75% of its employees following the U.S. FDA's decision earlier in August to reject its application for an MDMA-based...</p>\n\n<a href=\"https://seekingalpha.com/news/4140729-lykos-laying-off-75-workforce-following-fda-rejection-psychedelic-drug-ptsd\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://seekingalpha.com/news/4140729-lykos-laying-off-75-workforce-following-fda-rejection-psychedelic-drug-ptsd","article_id":"2459401548","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/882024294/image_882024294.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459401548","pubTimestamp":1723748562,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Lykos Therapeutics, the privately held psychedelic drug developer, is letting go of 75% of its employees following the U.S. FDA's decision earlier in August to reject its application for an MDMA-based drug to treat PTSD. In addition, Rick Doblin, the co-founder of the Multidisciplinary Association for Psychedelic Studies which incubated Lykos, is stepping down from the company's board.  David Hough, a former R&D exec with Johnson & Johnson Innovative Medicine, has been brought on to oversee discussions with the agency and clinical development going forward. Lykos has also formed an independent advisory board to support management through the midomafetamine resubmission process. Publicly traded psychedelic-focused drug developers include Mind Medicine , Atai Life Sciences , COMPASS Pathways , Cybin , and GH Research . Nano-caps include 180 Life Sciences , Enveric Biosciences , Seelos Therapeutics , SciSparc , Bright Minds Biosciences , and Clearmind Medicine .","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"FDA拒绝治疗PTSD的迷幻药后，Lykos裁员75%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATAI":1,"SPRC":1,"SEEL":1,"MNMD":1,"GHRS":1,"ENVB":1,"DRUG":1,"CYBN":1,"CMPS":1,"CMND":1,"ATNF":1,".IXIC":0.9,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"Lykos Therapeutics, the privately held psychedelic drug developer, is letting go of 75% of its employees following the U.S. FDA's decision earlier in August to reject its application for an MDMA-based drug to treat PTSD. In addition, Rick Doblin, the co-founder of the Multidisciplinary Association for Psychedelic Studies which incubated Lykos, is stepping down from the company's board.  David Hough, a former R&D exec with Johnson & Johnson Innovative Medicine, has been brought on to oversee discussions with the agency and clinical development going forward. Lykos has also formed an independent advisory board to support management through the midomafetamine resubmission process. Publicly traded psychedelic-focused drug developers include Mind Medicine (NASDAQ:MNMD), Atai Life Sciences (NASDAQ:ATAI), COMPASS Pathways (NASDAQ:CMPS), Cybin (CYBN), and GH Research (GHRS). Nano-caps include 180 Life Sciences (ATNF), Enveric Biosciences (ENVB), Seelos Therapeutics (NASDAQ:SEEL), SciSparc (SPRC), Bright Minds Biosciences (DRUG), and Clearmind Medicine (CMND).","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"Policy And Regulatory","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459401548"}